
1/2 @Bloomberg went inside Amgen @deCODE genetics in Iceland to get an exclusive look at how Amgen is using human DNA to shape our distinct approach to obesity research: bloomberg.com/news/videos/20… $AMGN

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases. 🔗 Guidelines: amgen.ly/RpcA3B

1/2 @Bloomberg went inside Amgen @deCODE genetics in Iceland to get an exclusive look at how Amgen is using human DNA to shape our distinct approach to obesity research: bloomberg.com/news/videos/20… $AMGN

No two obesity journeys look the same, which is why real progress in obesity care starts with listening. At #HLTHUSA, we’re putting that into practice. Watch Amy share her experience and learn why continued dialogue and understanding matter. 🔗 amgen.ly/3Xrlj3N


As we head into #HLTHUSA and #ObesityWeek, one thing is clear: the future of obesity care will be shaped by the conversations we have and actions we take together. By bringing together diverse voices, these meetings create opportunities to address the significant burdens that continue to impact millions of people living with obesity.

#SjogrensDisease news: Amgen presented late-breaking Phase 3 results at #ACR26. The study showed improvements in systemic disease activity and symptoms. 🔗 amgen.ly/4BWqWqw $AMGN

At AHA #ScientificSessions26, Amgen presented data highlighting the cost effectiveness of intensive LDL-C lowering, building on years of established clinical evidence. Read the press release: amgen.ly/4BU8qPs $AMGN

Why do some people develop heart disease while others don’t? Amgen research leader and AHA Population Research Prize recipient Pradeep Natarajan shares insights in a new Q&A article. amgen.ly/4iBF5Ra


📢 Amgen’s real-world study shows that treatment decisions to lower LDL-C impacts heart attack risk in ASCVD patients. The findings prompt a closer look at how we approach LDL-C lowering in clinical practice. 🔗 amgen.ly/47Z4v6A $AMGN

Amgen reports Q3 2026 earnings: amgen.ly/4iu1ik1 Amgen delivered another strong quarter, reflecting the performance our strategy was designed to achieve. Safe Harbor: amgen.ly/4iE0FER $AMGN

Amgen will report Q3 2026 earnings tomorrow. Details here: amgen.ly/4ivyiIB $AMGN


At AHA #ScientificSessions26, Amgen is adding to its extensive base of cardiovascular evidence, with new research exploring LDL-C management, long-term outcomes and the economic considerations of care. Explore our abstracts ⬇️

Every story is personal. Every voice can help bring our mission into focus. Meet people whose experiences with cancer, cardiovascular disease, rare disease and obesity have shaped their lives and perspectives. At Amgen, serving patients is our mission. We’re honored to be named to @TIME World’s Best Companies 2026 list: amgen.ly/4ipVlEY

Amgen will report Q3 2026 financial results on Tuesday, November 3. Details here: amgen.ly/4jM7dU0 $AMGN

Innovation has deep roots in Massachusetts, and Amgen is proud to have been part of its life sciences community for 25 years. From our research center in Cambridge, our teams continue to push the boundaries of science to advance medicines for patients around the world. Learn more about our history in Massachusetts: amgen.ly/4iqQtzr